{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-014674","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.123295+00:00","generated_at":"2026-06-17T08:57:54.948520+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocuphire Pharma reports Q4 2022 net income $33.9M, full-year net income $17.9M; cash $42.6M","bullets":["Net income $17.9M for 2022 vs net loss $56.7M in 2021; diluted EPS $0.87.","Revenue $39.9M from Nyxol license agreement with Viatris (upfront $35M).","Cash $42.6M, no debt, runway into 2025.","PDUFA date Sept 28, 2023 for Nyxol in reversal of mydriasis; $10M milestone upon approval.","APX3330 ZETA-1 trial achieved statistical significance on key endpoint; End-of-Phase 2 meeting planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-014674","json":"https://secwatch.observer/filing/0001140361-23-014674.json","markdown":"https://secwatch.observer/filing/0001140361-23-014674.md","text":"https://secwatch.observer/filing/0001140361-23-014674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123014674/0001140361-23-014674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123014674/brhc10050620_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:57:54.948520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"efd3e9bea8e4dc9669e084db6a8d8e054be5d37c","claim":"Opus Genetics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123014674/0001140361-23-014674-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}